U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C50H67N7O8.9H2O
Molecular Weight 1950.3557
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OMBITASVIR HEMINONAHYDRATE

SMILES

O.O.O.O.O.O.O.O.O.COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)C=C5.COC(=O)N[C@@H](C(C)C)C(=O)N7CCC[C@H]7C(=O)NC8=CC=C(C=C8)[C@@H]9CC[C@H](N9C%10=CC=C(C=C%10)C(C)(C)C)C%11=CC=C(NC(=O)[C@@H]%12CCCN%12C(=O)[C@@H](NC(=O)OC)C(C)C)C=C%11

InChI

InChIKey=AWMWWEBJJCSJHI-MVJJBPFMSA-N
InChI=1S/2C50H67N7O8.9H2O/c2*1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9;;;;;;;;;/h2*14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63);9*1H2/t2*38-,39-,40-,41-,42-,43-;;;;;;;;;/m00........./s1

HIDE SMILES / InChI

Molecular Formula C50H67N7O8
Molecular Weight 894.1091
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ombitasvir (ABT-267) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, has favorable pharmacokinetic characteristics and is active in the picomolar range against genotype 1 - 6. In 2015, it was approved by FDA for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1.

CNS Activity

Curator's Comment: Tissue distribution in rats was slow and did not permeate across the blood brain barrier or into the lens of the eye.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIEKIRA PAK (COPACKAGED)

Approved Use

VIEKIRA PAK with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.

Launch Date

2014
Primary
TECHNIVIE

Approved Use

TECHNIVIE is a fixed-dose combination of ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor and is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.

Launch Date

2015
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
68 ng/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PARITAPREVIR
[NO STEREO] OMBITASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1000 ng × h/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PARITAPREVIR
[NO STEREO] OMBITASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23 h
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PARITAPREVIR
[NO STEREO] OMBITASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PARITAPREVIR
[NO STEREO] OMBITASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
PubMed

PubMed

TitleDatePubMed
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
2014 Mar 13
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
2015 Sep
Patents

Sample Use Guides

The direct-acting antiviral regimen of 25 mg ombitasvir-150 mg paritaprevir-100 mg ritonavir once daily (QD) plus 250 mg dasabuvir twice daily (BID) is approved for the treatment of hepatitis C virus genotype 1 infection, including patients coinfected with human immunodeficiency virus.
Route of Administration: Oral
In vitro studies revealed that ABT-267 (ombitasvir) is a broad genotype NS5A inhibitor with antiviral activity in the picomolar range (EC50 1.7 -- 19.3 in genotype 1a, 1b, 2a, 3a, 4a and 5a, and 366 pM in genotype 6a).
Substance Class Chemical
Created
by admin
on Sat Dec 16 06:51:58 GMT 2023
Edited
by admin
on Sat Dec 16 06:51:58 GMT 2023
Record UNII
EQE3I70J3W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMBITASVIR HEMINONAHYDRATE
Common Name English
ABT-267 HEMINONAHYDRATE
Code English
L-PROLINAMIDE, 2,2'-(((2S,5S)-1-(4-(1,1-DIMETHYLETHYL)PHENYL)-2,5-PYRROLIDINEDIYL)DI-4,1-PHENYLENE)BIS(N-(METHOXYCARBONYL)-L-VALYL-, HYDRATE (2:9)
Systematic Name English
OMBITASVIR HYDRATE [JAN]
Common Name English
Code System Code Type Description
FDA UNII
EQE3I70J3W
Created by admin on Sat Dec 16 06:51:58 GMT 2023 , Edited by admin on Sat Dec 16 06:51:58 GMT 2023
PRIMARY
PUBCHEM
90479606
Created by admin on Sat Dec 16 06:51:58 GMT 2023 , Edited by admin on Sat Dec 16 06:51:58 GMT 2023
PRIMARY
RXCUI
1600437
Created by admin on Sat Dec 16 06:51:58 GMT 2023 , Edited by admin on Sat Dec 16 06:51:58 GMT 2023
PRIMARY RxNorm
CAS
1456607-70-7
Created by admin on Sat Dec 16 06:51:58 GMT 2023 , Edited by admin on Sat Dec 16 06:51:58 GMT 2023
PRIMARY
DRUG BANK
DBSALT002724
Created by admin on Sat Dec 16 06:51:58 GMT 2023 , Edited by admin on Sat Dec 16 06:51:58 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY